nach oben

Erschienen in:

01.05.2020 | Original Article

Immunohistochemical analysis of the expression of cancer-associated fibroblast markers in esophageal cancer with and without neoadjuvant therapy

verfasst von: José A. Galván, Julia Wiprächtiger, Julia Slotta-Huspenina, Marcus Feith, Katja Ott, Dino Kröll, Christian A. Seiler, Rupert Langer

Erschienen in: Virchows Archiv | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Esophageal carcinoma (EC) is one of the most aggressive human malignancies with high rates of resistance to conventional anticancer treatment. Cancer-associated fibroblasts (CAFs) are an important part of the tumor microenvironment and associated with tumor progression. COL11A1, SPARC, and CD90 have been identified as rather specific CAF markers, with COL11A1 expression particularly shown to influence response to chemotherapy. We investigated the impact of CAFs in esophageal cancer with a special focus on response to neoadjuvant treatment (nTX). Two collections of esophageal carcinomas were investigated: 164 cases treated with primary resection and 256 cases receiving nTX before resection. The expression of CAF markers was determined using next-generation tissue microarray (ngTMA®) technology and immunohistochemistry. The presence of COL11A1 and SPARC in fibroblasts within both primary resected cases and nTX-treated cases was associated with unfavorable clinicopathological variables such as higher (y)pT category and lymphatic invasion (p<0.001 each). The presence of COL11A1-positive CAFs was associated with worse overall survival in primary resected cases (HR: 2.162, p = 0.004, CI 95% 1.275–3.686). While in tumors showing regression after nTX, COL11A1-positive CAFs were detected less frequently, SPARC-positive CAFs were enriched after nTX, in both responding and non-responding patients (p < 0.001). Our results support the concept of CAFs as an important factor of tumor promotion and maintenance in EC. The population of CAFs increases with tumor progression and decreases, partly depending on the subtype, after regression following nTX. CAFs may serve as potential target for future therapeutic approaches for these highly aggressive tumors.

Nur mit Berechtigung zugänglich

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29. https://doi.org/10.3322/caac.20138 CrossRefPubMed

Langer R, Becker K (2018) Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch 472(2):175–186. https://doi.org/10.1007/s00428-017-2232-x CrossRefPubMed

Tommelein J, De Vlieghere E, Verset L, Melsens E, Leenders J, Descamps B, Debucquoy A, Vanhove C, Pauwels P, Gespach CP, Vral A, De Boeck A, Haustermans K, de Tullio P, Ceelen W, Demetter P, Boterberg T, Bracke M, De Wever O (2018) Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation. Cancer Res 78(3):659–670. https://doi.org/10.1158/0008-5472.CAN-17-0524 CrossRefPubMed

Verset L, Tommelein J, Moles Lopez X, Decaestecker C, Boterberg T, De Vlieghere E, Salmon I, Mareel M, Bracke M, De Wever O, Demetter P (2015) Impact of neoadjuvant therapy on cancer-associated fibroblasts in rectal cancer. Radiother Oncol 116(3):449–454. https://doi.org/10.1016/j.radonc.2015.05.007 CrossRefPubMed

Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Tweigeri T, Ajarim D, Alaiya A, Dermime S, Aboussekhra A (2008) Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 68(8):2717–2725. https://doi.org/10.1158/0008-5472.CAN-08-0192 CrossRefPubMed

Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116(7):1955–1962. https://doi.org/10.1172/JCI26532 CrossRefPubMedCentralPubMed

Zhang H, Xie C, Yue J, Jiang Z, Zhou R, Xie R, Wang Y, Wu S (2017) Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGFbeta1 signaling loop in esophageal squamous cell carcinoma. Mol Carcinog 56(3):1150–1163. https://doi.org/10.1002/mc.22581 CrossRefPubMed

Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ, Thirdborough S, Mead A, Clemons N, Mellone M, Uzoho C, Primrose JN, Blaydes JP, Thomas GJ (2015) Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. J Pathol 235(3):466–477. https://doi.org/10.1002/path.4467 CrossRefPubMedCentralPubMed

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167–3175. https://doi.org/10.1200/JCO.2009.26.7609 CrossRefPubMedCentralPubMed

10.

Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM (2002) Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 62(16):4767–4772PubMed

11.

Chung KM, Hsu SC, Chu YR, Lin MY, Jiaang WT, Chen RH, Chen X (2014) Fibroblast activation protein (FAP) is essential for the migration of bone marrow mesenchymal stem cells through RhoA activation. PLoS One 9(2):e88772. https://doi.org/10.1371/journal.pone.0088772 CrossRefPubMedCentralPubMed

12.

Kim H, Watkinson J, Varadan V, Anastassiou D (2010) Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genet 3:51. https://doi.org/10.1186/1755-8794-3-51 CrossRef

13.

Wu YH, Chang TH, Huang YF, Huang HD, Chou CY (2014) COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene 33(26):3432–3440. https://doi.org/10.1038/onc.2013.307 CrossRefPubMed

14.

Schliekelman MJ, Creighton CJ, Baird BN, Chen Y, Banerjee P, Bota-Rabassedas N, Ahn YH, Roybal JD, Chen F, Zhang Y, Mishra DK, Kim MP, Liu X, Mino B, Villalobos P, Rodriguez-Canales J, Behrens C, Wistuba II, Hanash SM, Kurie JM (2017) Thy-1(+) Cancer-associated fibroblasts adversely impact lung cancer prognosis. Sci Rep 7(1):6478. https://doi.org/10.1038/s41598-017-06922-5 CrossRefPubMedCentralPubMed

15.

Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530. https://doi.org/10.1002/cncr.11660 CrossRefPubMed

16.

Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253(5):934–939. https://doi.org/10.1097/SLA.0b013e318216f449 CrossRefPubMed

17.

Zlobec I, Suter G, Perren A, Lugli A (2014) A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies. J Vis Exp (91):e51893. https://doi.org/10.3791/51893

18.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2(8):416–422CrossRefPubMed

19.

Galván JA, García-Martínez J, Vázquez-Villa F, García-Ocaña M, García-Pravia C, Menéndez-Rodríguez P, González-del Rey C, Barneo-Serra L, de los Toyos JR (2014) Validation of COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma. BMC Cancer 14(1):867CrossRefPubMedPubMedCentral

20.

Li M, Li M, Yin T, Shi H, Wen Y, Zhang B, Chen M, Xu G, Ren K, Wei Y (2016) Targeting of cancer-associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Mol Med Rep 13(3):2476–2484. https://doi.org/10.3892/mmr.2016.4868 CrossRefPubMedCentralPubMed

21.

Jia D, Liu Z, Deng N, Tan TZ, Huang RY, Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE, Karlan BY, Orsulic S (2016) A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett 382(2):203–214. https://doi.org/10.1016/j.canlet.2016.09.001 CrossRefPubMedCentralPubMed

22.

García-Pravia C, Galván JA, Gutiérrez-Corral N, Solar-García L, García-Pérez E, García-Ocaña M, Del Amo-Iribarren J, Menéndez-Rodríguez P, García-García J, Juan R (2013) Overexpression of COL11A1 by cancer-associated fibroblasts: clinical relevance of a stromal marker in pancreatic cancer. PLoS One 8(10):e78327CrossRefPubMedPubMedCentral

23.

Vázquez-Villa F, García-Ocaña M, Galván JA, García-Martínez J, García-Pravia C, Menéndez-Rodríguez P, González-del Rey C, Barneo-Serra L, Juan R (2015) COL11A1/(pro) collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression. Tumor Biol 36(4):2213–2222CrossRef

24.

Shen L, Yang M, Lin Q, Zhang Z, Zhu B, Miao C (2016) COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep 36(2):877–885. https://doi.org/10.3892/or.2016.4869 CrossRefPubMed

25.

Wu YH, Chang TH, Huang YF, Chen CC, Chou CY (2015) COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPbeta pathway and PDK1 stabilization. Oncotarget 6(27):23748–23763. https://doi.org/10.18632/oncotarget.4250 CrossRefPubMedCentralPubMed

26.

He Y, Liu J, Zhao Z, Zhao H (2017) Bioinformatics analysis of gene expression profiles of esophageal squamous cell carcinoma. Dis Esophagus 30(5):1–8. https://doi.org/10.1093/dote/dow018 CrossRefPubMed

27.

Brown JA, Yonekubo Y, Hanson N, Sastre-Perona A, Basin A, Rytlewski JA, Dolgalev I, Meehan S, Tsirigos A, Beronja S, Schober M (2017) TGF-beta-induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma. Cell Stem Cell 21(5):650–664 e658. https://doi.org/10.1016/j.stem.2017.10.001 CrossRefPubMedCentralPubMed

28.

Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM (2014) Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer 110(3):724–732. https://doi.org/10.1038/bjc.2013.768 CrossRefPubMed

29.

van Staalduinen J, Baker D, Ten Dijke P, van Dam H (2018) Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene 37(48):6195–6211. https://doi.org/10.1038/s41388-018-0378-x CrossRefPubMed

30.

Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA, Orimo A (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 107(46):20009–20014. https://doi.org/10.1073/pnas.1013805107 CrossRefPubMedCentralPubMed

31.

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY, Orsulic S (2014) A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res 20(3):711–723. https://doi.org/10.1158/1078-0432.CCR-13-1256 CrossRefPubMed

32.

Wang T, Srivastava S, Hartman M, Buhari SA, Chan CW, Iau P, Khin LW, Wong A, Tan SH, Goh BC, Lee SC (2016) High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. Oncotarget 7 (34):55155–55168. https://doi.org/10.18632/oncotarget.10894

33.

Wu J, Zhang JR, Jiang XQ, Cao XG (2017) Correlation between secreted protein acidic and rich in cysteine protein expression and the prognosis of postoperative patients exhibiting esophageal squamous cell carcinoma. Mol Med Rep 16(3):3401–3406. https://doi.org/10.3892/mmr.2017.6959 CrossRefPubMed

34.

Chen Y, Zhang Y, Tan Y, Liu Z (2017) Clinical significance of SPARC in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 492(2):184–191. https://doi.org/10.1016/j.bbrc.2017.08.043 CrossRefPubMed

35.

Saalbach A, Hildebrandt G, Haustein UF, Anderegg U (2002) The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1- positive microvascular endothelial cells. Microvasc Res 64(1):86–93. https://doi.org/10.1006/mvre.2002.2401 CrossRefPubMed

36.

Tang KH, Dai YD, Tong M, Chan YP, Kwan PS, Fu L, Qin YR, Tsao SW, Lung HL, Lung ML, Tong DK, Law S, Chan KW, Ma S, Guan XY (2013) A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res 73(7):2322–2332. https://doi.org/10.1158/0008-5472.CAN-12-2991 CrossRefPubMed

37.

Li A, Li J, Lin J, Zhuo W, Si J (2017) COL11A1 is overexpressed in gastric cancer tissues and regulates proliferation, migration and invasion of HGC-27 gastric cancer cells in vitro. Oncol Rep 37(1):333–340. https://doi.org/10.3892/or.2016.5276 CrossRefPubMed

38.

Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA Jr, Sukhdeo K, DeVecchio J, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich JN (2013) Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 210(13):2851–2872. https://doi.org/10.1084/jem.20131195 CrossRefPubMedCentralPubMed

39.

Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C, Bonneau C, Kondratova M, Kuperstein I, Zinovyev A, Givel AM, Parrini MC, Soumelis V, Vincent-Salomon A, Mechta-Grigoriou F (2018) Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33(3):463–479 e410. https://doi.org/10.1016/j.ccell.2018.01.011 CrossRefPubMed

40.

Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H (2015) Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel) 7(4):2443–2458. https://doi.org/10.3390/cancers7040902 CrossRef

Titel: Immunohistochemical analysis of the expression of cancer-associated fibroblast markers in esophageal cancer with and without neoadjuvant therapy
verfasst von: José A. Galván
Julia Wiprächtiger
Julia Slotta-Huspenina
Marcus Feith
Katja Ott
Dino Kröll
Christian A. Seiler
Rupert Langer
Publikationsdatum: 01.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 5/2020
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02714-6

Springer Medizin

Immunohistochemical analysis of the expression of cancer-associated fibroblast markers in esophageal cancer with and without neoadjuvant therapy

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Lymphoproliferations at extranodal sites: a morphologically, genetically, and clinically diverse group of neoplasms with overlapping features

Correction to: Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas

Comparison of pathology sampling protocols for pancreatoduodenectomy specimens

The clinico-pathological spectrum of primary cutaneous lymphoma other than mycosis fungoides/Sezary syndrome

Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer

EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie